Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer
Conditions
- Esophageal Cancer
- Gastroesophageal Junction Cancer
Interventions
- DRUG: Sorafenib, administered orally
- PROCEDURE: CT/MRI
Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators